(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Blood pressure drug recalled for possible cross-contamination - 2Humpback whale stranded on Germany's Baltic coast frees itself
- 3One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- 4Most loved Web-based feature: Which Stage Do You Like
- 5The Most Compelling Innovation Advancements Somewhat recently
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Strengthening through Wellness: Individual Preparation Achievement
- Somaliland denies trading recognition with Israel for accepting Gazans
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- Which Instax Camera Would it be a good idea for you to Purchase?
- First SpaceX booster for upgraded Starship fails during test in Texas
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- Discovery of massive spider's web in Greece reveals unexpected behavior
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
